SHARING Z&A'S REPORT ON: Trulieve NYSE uplisting, peer implications, and questions that institutional investors will be asking as they start to enter the space (gradually... and then all at once?)
click this link for the report:
https://t.co/aVUPC1deaR
Mixed Q1 from @veranobrands. Revenue was better than expected (up sequentially despite a seasonally softer Q1), while margin challenges continued with aEBITDA at its lowest point as a public company (going back to 2021)
https://t.co/HaYbbi4yXE
Went back on the CIN podcast for the first time in a year, and timely with the recent rescheduling news. The usual financial review- this time the full 2025 year for $CURLF $CRLBF $GTBIF $TCNNF $VRNOF
Great summary by @Dentons of the DOJ order rescheduling medical cannabis including the framework for exports:
Breaking: DOJ Reschedules and Provides a Pathway for Full Legalization of Medical Cannabis
Nice week. 280e is GONE for medical marijuana. 2-week hearing has been scheduled for adult use cannabis to schedule 3. DOJ telling Treasury to refund 280e. JP Morgan and Morgan Stanley are buying $GTBIF. DEA license may be enough to uplist. Wild times.
$MSOS
NEW: A senior advisor to President Trump tells The Marijuana Herald that the president wants interim AG Todd Blanche to sign a final ruling rescheduling cannabis, rather than waiting for a permanent AG to be confirmed by the Senate. https://t.co/k7Ni7Cdv7f